Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Grace Therapeutics, Inc. (GRCE : NSDQ)

• Company Description    Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $2.99 Daily Weekly Monthly 20 Day Moving Average: 63,965 shares Shares Outstanding: 13.83 (millions) Market Capitalization: $41.35 (millions) Beta: 0.99 52 Week High: $4.97 52 Week Low: $1.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -2.62% 12 Week -8.28% -12.09% Year To Date -20.05% -30.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 103 CARNEGIE CENTER SUITE 300 - PRINCETON,NJ 08540 CAN ph: 609-322-1602 fax: 45-0687-2272 acst@crescendo-ir.com http://www.acastipharma.com

• General Corporate Information    Officers Prashant Kohli - Chief Executive Officer Robert DelAversano - Principal Financial Officer Brian Davis - Director Vimal Kavuru - Director Edward Neugeboren - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00439U104 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 13.83 Most Recent Split Date: 7.00 (0.17:1) Beta: 0.99 Market Capitalization: $41.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 12.50% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -20.36 03/31/25 - -19.45 ROA 09/30/25 - - 06/30/25 - -18.09 03/31/25 - -16.99 Current Ratio 09/30/25 - - 06/30/25 - 8.87 03/31/25 - 11.77 Quick Ratio 09/30/25 - - 06/30/25 - 8.87 03/31/25 - 11.77 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.60 03/31/25 - 4.86 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©